Cantor Fitzgerald raises Prenetics price target on strong quarterly results

Cantor Fitzgerald raised its price target on Prenetics (PRE) to $14 from $13, maintaining an Overweight rating after the company reported Q1 2025 revenue of $17.3 million, a 170% year-over-year increase driven by its IM8 and Europa business lines. The firm highlighted Prenetics' increased 2025 guidance and its valuation at 0.6x enterprise value to estimated 2025 revenue, significantly lower than peers, while the company plans to divest ACT Genomics and convert its balance sheet to cryptocurrency.

Analysis

Cantor Fitzgerald has increased its price target for Prenetics (NASDAQ:PRE) to $14.00 from $13.00, maintaining an Overweight rating, following the company's first-quarter 2025 financial results which, according to InvestingPro analysis, suggest the stock is undervalued. This new target represents a 100% potential upside from its current price of $7.01. Prenetics reported Q1 2025 revenue from continuing operations of $17.3 million, marking a significant year-over-year growth of approximately 170%, predominantly driven by its IM8 and Europa business lines. The IM8 product, commercially launched at the end of Q4 2024, contributed approximately $5.7 million in revenue, and the company anticipates IM8 revenue will grow by roughly 50% in the second quarter. Supporting this positive outlook, Prenetics has demonstrated impressive trailing twelve-month revenue growth of 78.7% and maintains a healthy current ratio of 2.07x. The company has also increased its 2025 guidance and is focused on reaching breakeven. Valuation metrics appear favorable, with Prenetics trading at 0.6 times enterprise value to estimated 2025 revenue, a stark contrast to slower-growing peers trading at 6.1 times, and a price-to-book ratio of 0.57x. Strategic plans include divesting its ACT Genomics business and converting its balance sheet to cryptocurrency assets.

Key Decisions for Investors

• Investors should consider the potential for significant share price appreciation given Cantor Fitzgerald's $14 price target, the Overweight rating, and Prenetics' current valuation at a substantial discount to peers.
• The robust revenue growth, fueled by new products like IM8, and the company's upwardly revised 2025 guidance signal strong operational momentum; however, progress towards achieving breakeven should be closely monitored.
• The strategic initiatives, including the divestment of ACT Genomics and the unconventional plan to convert balance sheet assets to cryptocurrency, present both unique growth avenues and heightened risk factors that require careful due diligence and continuous assessment.